NASDAQ:VSAR - Versartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.40 0.00 (0.00 %)
(As of 06/20/2018 03:24 AM ET)
Previous Close$2.40
Today's Range$2.25 - $2.45
52-Week Range$1.35 - $22.10
Volume667,116 shs
Average Volume616,221 shs
Market Capitalization$88.40 million
P/E Ratio-1.00
Dividend YieldN/A
Beta2.07
Versartis logoVersartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VSAR
CUSIPN/A
Phone650-963-8580

Debt

Debt-to-Equity Ratio0.09
Current Ratio21.29
Quick Ratio21.29

Price-To-Earnings

Trailing P/E Ratio-1.00
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales2,164.80
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book1.04

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-84,970,000.00
Net MarginsN/A
Return on Equity-84.63%
Return on Assets-53.05%

Miscellaneous

Employees28
Outstanding Shares36,080,000

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.61. View Versartis' Earnings History.

When is Versartis' next earnings date?

Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Versartis.

What price target have analysts set for VSAR?

9 analysts have issued 12-month price objectives for Versartis' stock. Their forecasts range from $3.00 to $14.00. On average, they anticipate Versartis' share price to reach $5.1250 in the next year. View Analyst Ratings for Versartis.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:
  • Mr. Jay P. Shepard, CEO, Pres, Principal Financial Officer & Director (Age 60)
  • Dr. Jeffrey L. Cleland, Co-Founder and Sr. Scientific Advisor to the Chief Exec. Officer (Age 53)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Kevin Haas, VP of Fin. & Principal Accounting Officer (Age 53)
  • Mr. Shane M. Ward, Sr. VP & Gen. Counsel (Age 43)

Has Versartis been receiving favorable news coverage?

News stories about VSAR stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Versartis earned a news sentiment score of 0.13 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.47 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Versartis' major shareholders?

Versartis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Guggenheim Capital LLC (2.31%), Dimensional Fund Advisors LP (1.71%), GSA Capital Partners LLP (0.44%), JPMorgan Chase & Co. (0.39%), Schwab Charles Investment Management Inc. (0.36%) and A.R.T. Advisors LLC (0.25%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay S Stout, Jay Shepard, John Varian, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Perceptive Advisors Llc, Shahzad Malik, Shane Ward, Srinivas Akkaraju and Tracy M Woody. View Institutional Ownership Trends for Versartis.

Which major investors are selling Versartis stock?

VSAR stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and Guggenheim Capital LLC. Company insiders that have sold Versartis company stock in the last year include Colin Hislop, Jay S Stout, Jay Shepard, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Shane Ward and Tracy M Woody. View Insider Buying and Selling for Versartis.

Which major investors are buying Versartis stock?

VSAR stock was bought by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC, Schwab Charles Investment Management Inc., California Public Employees Retirement System, Dimensional Fund Advisors LP and GSA Capital Partners LLP. Company insiders that have bought Versartis stock in the last two years include Perceptive Advisors Llc and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy shares of Versartis?

Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $2.40.

How big of a company is Versartis?

Versartis has a market capitalization of $88.40 million and generates $40,000.00 in revenue each year. The biopharmaceutical company earns $-84,970,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Versartis employs 28 workers across the globe.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]


MarketBeat Community Rating for Versartis (VSAR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.